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Introduction 
Cell growth, differentiation, migration, and apoptosis are 
in part regulated by polypeptide growth factors or cyto- 
kines. As these factors are unable to pass the hydrophobic 
cell membrane, a fundamental question is how they trans- 
duce their signals into the cell. Growth factors and cyto- 
kines exert their effects via binding to cell surface recep- 
tors; results obtained during recent years have given 
ample evidence that such receptors often are activated by 
ligand-induced imerization or oligomerization. Moreover, 
the elucidation of intracellular signal transduction path- 
ways have revealed that the activity of several components 
in these pathways are also regulated by dimerization. For 
instance, certain of the cytoplasmic signal transduction 
molecules dimerize after activation, and the active form 
of transcription factors are often dimers. It thus appears 
that dimerization is a mechanism of general applicability 
for the regulation of signal transduction. 
This review focuses on the role of dimerization of cell 
surface receptors in signal transduction. Dimerization or 
oligomerization have been shown to occur after binding 
of several polypeptide hormones, cytokines, growth fac- 
tors, or growth inhibitors to their receptors. Examples in- 
clude protein-tyrosine kinase receptors, cytokine recep- 
tors, antigen receptors, receptors for tumor necrosis factor 
(TNF) and related factors, and serine/threonine kinase re- 
ceptors (Figure 1; Table 1). There are, however, many 
variations on the theme, as will be discussed below. 
Protein-Tyrosine Kinase Receptors 
Many traditional growth factors, such as platelet-derived 
growth factor (PDGF), epidermal growth factor (EGF), and 
fibroblast growth factor (FGF), bind to receptors with tyro- 
sine kinase activity (Table 1). Protein-tyrosine kinase re- 
ceptors consist of single transmembrane domains sepa- 
rating the intracellular kinase domains from extracellular 
domains, which typically contain one or several copies 
of immunoglobulin-like domains, fibronectin type Ill-like 
domains, EGF-like domains, cysteine-rich domains, or 
other domains (reviewed by Fantl et al., 1993). Based on 
their structural characteristics, the tyrosine kinase recep- 
tors can be classified into families; the largest families are 
listed in Table 1. 
Several of the ligands for protein-tyrosine kinase recep- 
tors are dimeric molecules, which thus contain two identi- 
cal receptor-binding epitopes. Examples include PDGF 
and colony-stimulating factor 1 (CSF-1), which are disul- 
fide-bonded dimers, and stem cell factor (SCF), which is a 
dimer held together by noncovalent forces. These ligands 
form stable receptor dimers by simultaneously binding two 
receptors. In addition to the bridging of the ligand between 
two receptors, it is possible that direct interactions be- 
tween the receptors, involving epitopes located outside 
the ligand-binding domains, are important for stabilization 
of the receptor dimer. In the case of the SCF receptor, 
evidence has been presented that epitopes in the fourth 
immunoglobulin domain are involved in such receptor- 
receptor interactions (Blechman et al., 1995). It is possible 
that such direct receptor-receptor interactions are pro- 
moted by conformational changes in the receptors in- 
duced by ligand binding. Other ligands, like EGF, have 
apparent monomeric configurations; interestingly, how- 
ever, recent calorimetric studies have shown that a single 
EGF molecule also can bind simultaneously to two recep- 
tor molecules (Lemmon and Schlessinger, 1994). Another 
variation on the theme is exemplified by ligands for Eph- 
related tyrosine kinase receptors. These ligands are cell 
surface attached and do not activate receptors in soluble 
form. The possibility that receptor dimerization or clustering 
is involved in receptor activation, presumably facilatated 
by membrane attachment of ligands, is supported by the 
finding that antibody-mediated clustering of soluble recep- 
tors led to activation of receptors (Davis et al., 1994). 
Receptor Autophosphorylation 
Dimerization of protein-tyrosine kinase receptors is fol- 
lowed by receptor"autophosphorylation," which mainly oc- 
curs by one receptor molecule phosphorylating the other 
in the dimer (UIIrich and Schlessinger, 1990). The auto- 
phosphorylation occurs on two principally different classes 
of tyrosine residues. On one hand, autophosphorylation 
is commonly seen on a conserved tyrosine residue within 
the kinase domains (Tyr-857 in the PDGF 13 receptor; Fig- 
ure 2). In the cases of the receptors for insulin and hepato- 
cyte growth factor (HGF), phosphorylation of the tyrosine 
residue at this and neighboring sites leads to an increase in 
the kinase activity and precedes phosphorylation of other 
sites in the receptor or substrates (Naldini et al., 1991; 
White et al., 1988). This thus appears to be an allosteric 
site that regulates the Vm~x of the receptor kinase. It is still 
not known how the autophosphorylation is initiated; one 
possibility is that the monomeric receptor has a low basal 
kinase activity, which is sufficient to phosphorylate and 
activate the companion receptor after dimerization. This 
would then rapidly be followed by reciprocal phosphoryla- 
tion. Alternatively, the interaction between the intracellular 
domains of the receptors in the dimer may induce a confor- 
mational change that leads to an increased kinase activity. 
Not all receptors are regulated by phosphorylation inside 
the kinase domain, e.g., in the EGF receptor, the con- 
served tyrosine residue in the kinase domain appears not 
to be autophosphorylated. 
The other class of autophosphorylation sites are nor- 
mally localized outside the kinase domains and serve the 
important function of creating docking sites for down- 
stream signal transduction molecules containing Src- 
homology 2 (SH2) domains. The SH2 domains consists 
of about 100 amino acid residues folded in such a way 
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Figure 1. Examples of Receptors Activated by 
Dimerization or Oligemerization 
Schematic representations of the complexes 
formed after ligand binding to receptors from 
the families discussed in the text, i.e., protein- 
tyrosine kinase receptors (the EGF receptor 
shown as an example), cytokine receptors (GH 
receptor bound to JAK kinases), antigen recep- 
tors (TCR), trimeric receptors (TNF receptor), 
and serine/threonine kinase receptors (TGF~ 
receptor). Tyrosine kinase domains are closed 
and serine/threonine kinase domains dark stip- 
pled. Box1, box2 (light stippled), refers to a re- 
gion in cytokine receptors to which JAK kinases 
bind. ARAM (light stippled) refers to antigen 
recognition activation motifs in different sub- 
units of antigen receptors that become phos- 
phorylated by tyrosine kinases of the Src family 
and thereafter bind tyrosine kinases of the 
ZAP-70/Syk family. 
Table 1. Families of Receptors Activated by Dimerization or Oligomerization 
Receptor Type Family Examples Characteristics 
Protein-tyrosine kinase receptors 
Cytokine receptors 
TNF receptor family 
Antigen receptors 
Serine/threonine kinase 
receptor family 
PDGF receptor family 
EGF receptor family 
FGF receptor family 
IGF receptor family 
HGF receptor family 
VEGF receptor family 
Neurotrophin receptor family 
Eph receptor family 
Class I cytokine receptor family 
GH receptor subfamily 
IL-3 receptor subfamily 
IL-6 receptor subfamily 
IL-2 receptor subfamily 
Class II cytokine receptor family 
Type II receptor family 
PDGFR-(~, PDGFR-13, SCFR (Kit), 
CSF-R (Fms), FIk-2 
EGFR (ErbB), ErbB2 (Neu), 
ErbB3, ErbB4 
FGFR-1, FGFR-2, FGFR-3, 
FGFR-4 
insulin R, IGF-1R 
HGFR (Met), MSPR (Ron) 
Fit-l, FIk-1 (KDR) 
Trk, TrkB, TrkC 
Eph, Elk, Eck, Cck5, Sek, Eck, Erk 
GHR, EPOR, PRLR, G-CSFR 
IL-3R, GM-CSFR, IL-5R 
IL-6R, LIFR, CNTFR, IL-11R 
IL-2Ra, IL-2r13, IL-4R, IL-7R 
IFN-a/I~R, IFN-~,Ra, IFN-TRI~, 
IL-10R 
TNFR-1, TNFR-II, LNGFR, CD40, 
OX-4O, Fas, CD27, CD30 
TCR 
BCR 
TGFI3R-II, ActR-II, ActR-IIB 
Five immunoglobulin-Iike 
domains extracellularly 
Two cysteine-rich domains 
extracellularly 
Two to three immunoglobulin-like 
domains extracellularly 
Disulphide-bound heterotetramer 
of a and 13 chains 
Extracellular domain cleaved into 
an (1 and I~ chain 
Seven immunoglobulin-like 
domains extracellularly 
Two FNIIl-like domains and a 
cysteine-rich domain 
extracellularly 
Form homodimers 
Form complexes with the I~o 
subunit 
Form complexes with gp130 
Form complexes with IL-2R~, 
Form trimers 
Complex of a, 13, ~, 8, ~, ~ an ~] 
subunits 
Complex of IgM and heterodimers 
of (~/1~ subunits 
Form hetero-oligomers with type I 
receptors, i.e., TGFI3R-I, 
ActR-1, ActR-1 B, 
BMPR-IA, BMPR-IB, ALK-1 
Receptor families and subfamilies discussed in the text are presented. Abbreviations used: R, receptor; PDGF, platelet-derived growth factor; 
SCF, stem cell factor; CSF, colony-stimulating factor; EGF, epidermal growth factor; FGF, fibroblast growth factor; IGF, insulin-like growth factor; 
HGF, hepatocyte growth factor; MSP, macrophage-stimulating protein; VEGF, vascular endothelial growth factor; FN, fibronectin; GH, growth 
hormone; EPO, erythropoietin; PRL, prolactin; IL, interleukin; LIF, leukemia inhibitory factor; CNTF, ciliary neurotrophic factor; IFN, interferon; 
TNF, tumor necrosis factor; LNGFR, low affinity nerve growth factor receptor; TCR, T cell receptor; BCR, B cell receptor; TGFI~, transforming 
growth factor 13; Act, activin; BMP, bone morphogenic protein. Alternative designations are given within parentheses. 
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Figure 2. InteractionofSH2Domain-ContainingSignalTransduction 
Molecules with Different Autophosphorylation Sites in the PDGF 13 Re- 
ceptor 
Schematic illustration ofthe intracellular portion of a PDGF ~, receptor 
after activation. The kinase domain (closed boxes) in the receptor is 
divided into two parts by an inserted sequence. The tyrosine residues 
in the receptor known to be autophosphorylated are indicated by num- 
bers. The interaction of individual autophosphorylated tyrosine resi- 
dues with different SH2 domain-containing proteins are also indicated. 
Shc, Grb2, and Nck are adaptor molecules; Src denotes different mem- 
bers of the Src family of tyrosine kinases; PI3-kinase, phosphatidytino- 
sitol 3'-kinase; GAP, GTPase-activating protein; PTP1 D, protein tyro- 
sine phosphatase 1D; PLC-7, phospholipase C-7. 
that a binding pocket for a phosphorylated tyrosine and the 
immediately surrounding amino acid residues is formed 
(Pawson and Schlessinger, 1993; Cohen et al., 1995 [this 
issue of Cell]). Of particular importance are the three to 
six amino acid residues C-terminal of the phosphorylated 
tyrosine (Eck et al., 1993; Pascal et al., 1994; Waksman 
et al., 1993); since different SH2 domains have different 
preferences for this region, there is specificity in the inter- 
action. As an example, the PDGF 13 receptor has been 
shown to contain at least nine autophosphorylated tyro- 
sine residues; Tyr-857 in the second part of the kinase 
domain is of importance for the catalytic activity of the 
kinase, whereas the others interact in a specific manner 
with at least eight different signal transduction molecules 
(reviewed by Claesson-Welsh, 1994; Figure 2). 
Homodimerization or Heterodimerization 
Protein-tyrosine kinase receptors are activated after ho- 
modimerization or after heterodimerization. In the case of 
the PDGF receptor subfamily, the different isoforms of 
PDGF induce different dimeric forms of the receptors. 
Since the A chain of PDGF binds only a receptors while 
the B chain binds both a and 13 receptors with high affinity, 
PDGF-AA induces ~a receptor homodimers only, PDGF- 
AB induces aa receptor homodimers and ~13 receptor het- 
erodimers, and PDGF-BB induces all three combinations 
of receptors (Heldin et al., 1989; Kanakaraj et al., 1991; 
Seifert et al., 1989). There are certain differences in the 
signals transduced via ~ receptor homodimers and I~ 
receptor homodimers, e.g., regarding the stimulation of 
chemotaxis and actin reorganization. Moreover, PDGF- 
AB, which preferentially induces a13 receptor dimers, in- 
duces a stronger mitogenic response than the other PDGF 
isoforms. A possible explanation for the unique properties 
of the ~13 receptor heterodimer is the presence of unique 
autophosphorytation sites, not seen in the homodimeric 
receptors, and that may mediate interactions with addi- 
tional signal transduction molecules (Rupp et al., 1994). 
Thus, the response to PDGF depends both on the particu- 
lar isoform of PDGF and on the number of ~ and 13 recep- 
tors expressed on the target cells. 
The EGF receptor was the first protein-tyrosine kinase 
receptor to be shown to dimerize after ligand binding (Yar- 
den and Schlessinger, 1987). However, within the same 
subfamily of tyrosine kinase receptors, heterodimerization 
of receptors has also been observed. A candidate ligand 
for ErbB2 (Neu differentiation factor [NDF], also called 
heregulin, glial growth factor, or acetylcholin-receptor- 
inducing activity), which is structurally related to EGF, was 
found to induce heterodimeric omplexes between ErbB2 
and ErbB3 or ErbB4 (Peles et al., 1993; Plowman et al., 
1993; Sliwkowski et al., 1994). Moreover, the presence of 
ErbB3 or ErbB4 was necessary for high affinity binding 
of NDF and signal transduction through ErbB2 to occur. 
Interestingly, ErbB3 lacks certain highly conserved amino 
acid residues in its kinase domain; consistent with this 
finding, ErbB3 was found to have low or no kinase activity 
(Prigent and Gullick, 1994). It is thus possible that the 
major function of ErbB3 in the heterodimer is to act as a 
substrate for the ErbB2 kinase and thus provide docking 
sites for downstream SH2 domain-containing signal 
transduction molecules (Carraway and Cantley, 1994); for 
example, binding motifs for the SH2 domains of the phos- 
phatidylinositol 3'-kinase (PI3-kinase) are lacking in the 
EGF receptor and in ErbB2, but occur in several copies 
in ErbB3 (Fedi et al., 1994; Soltoff et al., 1994). Also, EGF 
itself can induce heterodimerization of EGF receptors and 
ErbB2 (Soltoff et al., 1994; Wada et al., 1990). In fact, 
heterodimerization is preferred in cells expressing both 
EGF receptors and ErbB2. Although heterodimerization 
occurred also with a kinase-inactivated ErbB2 receptor 
mutant, this complex was inactive, showing that in this 
case signaling can not occur via ErbB2 serving as a EGF 
receptor substrate (Qian et al., 1994). 
The studies on dimerization of receptors in the PDGF 
receptor and EG F receptor families thus provide examples 
of different types of dimeric complexes induced after li- 
gand binding, i.e., homodimeric (Figure 3A) or heterodi- 
meric (Figure 3B) complexes between two catalytically ac- 
tive subunits, or a heterodimeric omplex between one 
active and one inactive or less active subunit (Figure 3C). 
Given that tyrosine kinase receptors and ligands occur in 
families of structurally related molecules, it is not unlikely 
that homodimerization and heterodimerization of recep- 
tors occur in parallel also in other families, thus increasing 
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Figure 3. DifferentDimericComplexesofProtein-TyrosineKinaseRe- 
ceptors 
Schematic representation ofdifferent forms of dimeric omplexes of 
tyrosine kinase receptors formed after ligand binding. (A) a homodi- 
meric complex; (B) a heterodimeric complex of two kinase-active sub- 
units; (C) a heterodimeric complex of one active and one inactive or 
less active subunit. 
the range of responses possible from a given number of 
receptor molecules. 
One special case is the insulin and insulin-like growth 
factor 1 (IGF-1) receptor family. These receptors exist in 
the cell membrane as disulfide-bonded homo- or hetero- 
dimers of receptor subunits (each subunit is further 
cleaved into a and 13 chains by proteolysis) (Soos and Sid- 
die, 1989). Thus, ligand binding does not induce receptor 
dimerization, but presumably causes a conformational al- 
teration in the preformed dimeric receptor, which leads to 
receptor activation. Moreover, autophosphorylated tyro- 
sine residues in the receptor molecules are not so im- 
portant for the binding of downstream components in the 
signal transduction pathways; rather, the insulin receptor 
kinase phosphorylates insulin receptor substrate 1 (IRS-1), 
which mediates the interactions with SH2 domain proteins 
(White, 1994). 
Cytokine Receptors 
The cytokine receptor classes include receptors for many 
interleukins, colony-stimulating factors, interferons, and 
certain other factors and hormones (reviewed by Kishi- 
moto et al., 1994; Mui and Miyajima, 1994; see Table 1). 
Class I cytokine receptors are characterized by the pres- 
ence in their extracellular domains of one or two copies 
of a conserved domain of about 200 amino acids, which 
contains two modules of fibronectin type Ill-like motifs, 
four conserved cysteine residues, and the conserved motif 
Trp-Ser-Xaa-Trp-Ser (Bazan, 1990). Class II cysteine 
receptors, including receptors for interferons and interleu- 
kin-10 (I L-10), contain another conserved motif of four cys- 
teine residues and lack the Trp-Ser-Xaa-Trp-Ser motif. 
The intracellular domains of cytokine receptors lack intrin- 
sic enzymatic activities. However, despite the structural 
difference between cytokine receptors and tyrosine kinase 
receptors, their mechanism of activation appears to be 
similar. Ligand binding induces dimerization or oligomer- 
ization of cytokine receptors, and this allows interaction 
and activation of cytoplasmic protein-tyrosine kinases that 
are associated with the intracellular domain of the receptors. 
Activation of Class I Cytokine Receptors through 
Formation of Hetero.Oligomeric Complexes 
Most of the class I cytokine receptors undergo heterodi- 
merization or hetero-oligomerization after ligand binding 
(Table 1). In many cases, the ligand-binding subunit(s) 
form signaling complexes with signal-transducing mole- 
cules that are structurally related to cytokine receptors, 
but that are themselves unable to bind ligands. For in- 
stance IL-3, granulocyte/macrophage colony-stimulating 
factor (GM-CSF), and IL-5 bind to specific (~ subunit recep- 
tors; the ct subunits all interact with a common [3 subunit 
that is required for high affinity ligand binding and signal 
transduction (Mui and Miyajima, 1994). 
Similarly, IL-6, leukemia inhibitory factor (LIF), onco- 
statin M, IL-11, and ciliary neurotrophic factor (CNTF) 
share a common signal transducer, gp130 (Taga et al., 
1989); signaling is triggered by the formation of homo- or 
heterodimers of gp130. IL-6 binds to the IL-6 receptor and 
induces a complex containing a homodimer of gp130 (Mur- 
akami et al., 1993). Interestingly, signaling occurs also 
with a truncated IL-6 receptor lacking the cytoplasmic do- 
main, which indicates that the IL-6 receptor is needed only 
to increase the binding affinty for IL-6. The CNTF receptor 
acts similarly, lacking a cytoplasmic domain in its natural 
form and being anchored in the membrane through a phos- 
phatidylinositol group. The CNTF receptor-CNTF com- 
plex signals via formation of a heteromeric complex of 
gp130 and the LIF receptor (Davis et al., 1993). LIF and 
oncostatin M signal via binding directly to a heteromeric 
complex of gp130 and the LIF receptor (Gearing et al., 
1992). IL-11 is dependent on gp130 but not the LIF recep- 
tor for signaling (Hilton et al., 1994). 
A third subfamily is constituted by IL-2, IL-4, iL-7, and 
IL-9. In this family, signaling involves the formation of het- 
erodimeric receptor complexes between specific 13 sub- 
units and a common ~, subunit (Kawahara et al., 1994). In 
the case of IL-2, the ligand binding affinity is increased 
by the presence also of an (z subunit, which has a structure 
unrelated to that of cytokine receptors. Whereas the (~ 
subunit is not needed for signal transduction, both the [3 
and the y subunits are needed, presumably in a heterodi- 
meric configuration (Nakamura et al., 1994; Nelson et al., 
1994). 
Activation by Homodimerization 
Although activation by heterodimerization appears to be 
most common among cytokine receptors, there are exam- 
ples of cytokine receptors that are activated by homodi- 
merization, e.g., the receptors for growth hormone (GH), 
erythropoietin (EPO), prolactin, and granulocyte colony- 
stimulating factor (G-CSF) (Table 1). A well-characterized 
example is the GH receptor. Analysis of crystals of GH 
and the extracellular part of the receptor revealed that 
each ligand binds two receptor molecules simultaneously 
(Cunningham et al., 1991; de Vos et al., 1992; UItsch et 
al., 1991). This finding was surprising since GH is a mono- 
meric molecule without apparent symmetry. The two re- 
ceptor-binding sites in GH are therefore different, although 
they bind to similar epitopes in the receptors. Site 1 is 
larger and is supposed to bind receptor first; the smaller 
site 2 thereafter binds a second receptor, and the dimeric 
receptor complex is further stabilized by direct interaction 
between the two receptors. The importance of the latter 
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epitope in stabilizing a GH receptor dimer is illustrated by 
the finding that a mutation in this region abolishes receptor 
homodimerization and is responsible for a form of familial 
GH resistance (Laron's syndrome; Duquesnoy et al., 
1994). The results from the three-dimensional structure 
studies are supported by titration calorimetry in solution; 
the heat of binding was found to be saturated at a 1:2 ratio 
of ligand and receptor (Ultsch et al., 1991). 
Signal Transduction 
Much information regarding the signal transduction path- 
ways from cytokine receptors to the nucleus has come 
from a genetic approach in which mutant cell lines defec- 
tive in the response to interferons were isolated and char- 
acterized (Darnell et al., 1994). This approach led to the 
identification of three categories of proteins, a DNA- 
binding protein (p48), STATs (signal transducers and acti- 
vators of transcription), and cytoplasmic protein-tyrosine 
kinases of the JAK family. 
The JAK kinases are characterized by the presence of 
two kinase domains in each molecule, which is the basis 
for their name (Janus kinases, after the Roman god with 
two faces) (reviewed by Ziemiecki et al., 1994). Several 
members of this family are currently known (JAK1, JAK2, 
Tyk2, JAK3 [Ziemiecki et al., 1994; Takahashi and Shira- 
sawa, 1994]); they associate in a specific manner with 
different cytokine receptors and are activated upon recep- 
tor dimerization. An important class of substrates for JAK 
kinases is members of the STAT family (STATI~, STAT113, 
STAT2, STAT3, STAT4, STAT5, and IL-4 STAT) (Darnell 
et al., 1994; Zhong et al., 1994; Gouilleux et al., 1994; 
Hou et al., 1994). After phosphorylation on tyrosine resi- 
dues, the STAT molecules form homo- or heterodimers. 
In the case of signaling from the interferon-a receptor, 
heterodimers of STATla (p91) or STATI~ (p84) and 
STAT2 (p113) are created, which move into the nucleus 
and form a complex with a DNA-binding protein (p48), 
allowing them to bind and stimulate transcription from ele- 
ments in the promoters of interferon-m-induced genes 
(Schindler et al., 1992). Interestingly, another combination 
of STATs is formed after stimulation by interferon-7, either 
a homodimer of STAT1 ct (p91) or a homodimer of STAT113 
(p84) (Shuai et al., 1994; Shuai et al., 1992). These dimers 
do not associate with p48, but may form complexes with 
other related proteins. Both homodimers bind to inter- 
feron-y-activated sites (GAS), which are present in inter- 
feron-7-inducible genes, although only the STATI~ homo- 
dimer activates transcription (Shuai et al., 1993). 
It thus appears that the activities of STATs are regulated 
by specific assembly into homo- or heterodimers. The di- 
merization is triggered by phosphorylation. A single phos- 
phorylated tyrosine residue has been identified in STAT1 
after stimulation with interferon-a as well as after stimula- 
tion with interferon-y; mutation of this tyrosine residue to 
a phenylalanine residue prevents dimerization (Shuai et 
al., 1993). Since STATs contain SH2 domains, it is likely 
that the dimerization involves reciprocal interactions be- 
tween the SH2 domains and the tyrosine-phosphorylated 
regions in the STAT molecules (Shuai et al., 1994). How 
is the specificity regulated? One possibility is that STATs 
may associate in a differential manner with different recep- 
tors (Fu and Zhang, 1993; Greenlund et al., 1994). 
Another possibility is that the JAK family members differ 
in their substrate specificities and thus phosphorylate dif- 
ferent STAT molecules. Interestingly, the genetic ap- 
proach led to the identification of different JAK kinases in 
the signaling pathways of interferon-c~ (JAK1 and Tyk2) 
and interferon-7 (JAK1 and JAK2) (M011er et al., 1993; Vel- 
azques et al., 1992; Watling et al., 1993). Thus, in each 
case, there was a need for two different JAK kinases. It 
is unlikely that the two kinases are needed in a sequential 
activation mechanism, since in cells deficient in JAK1 no 
activation of JAK2 was seen after stimulation with inter- 
feron-7, or vice versa (MLiller et al., 1993). Thus, it is possi- 
ble that the active forms of the JAK kinases involved in 
the signal pathways of interferons are activated by hetero- 
meric interactions, possibly involving cross-phosphoryla- 
tions. 
A possible mechanism to achieve such heterodimeriza- 
tion is via ligand-dependent formation of heteromeric re- 
ceptor complexes. The receptor for interferon-~, consists 
of at least two different chains (Aguet et al., 1988; Hemmi 
et al., 1994; Soh et al., 1994), and it has been suggested 
that JAK1 and JAK2 interact with these chains in a differen- 
tial manner (Greenlund et al., 1994). An interferon-aS re- 
ceptor that binds JAK1 has been identified (Novick et al., 
1994); whether another receptor subunit with affinity for 
Tyk2 exists remains to be elucidated. An analogous situa- 
tion appears to prevail for the IL-2 receptors; the 13 and Y 
subunits have been shown to bind JAK1 and JAK3, respec- 
tively (Miyazaki et al., 1994; Russell et al., 1994). 
Common and Unique Signals 
In addition to the receptors for interferon-~ and inter- 
feron-~,, many other receptors, including GH, EPO, prolac- 
tin, G-CSF, LIF, gp130, the common 13 subunit for the IL-3 
subfamily of receptors, and the common ¥ subunit for the 
IL-2 subfamily, have been shown to bind different mem- 
bers of the JAK family (Ihle et al., 1994). JAKs bind in a 
specific manner to conserved regions called box 1 and box 
2 regions in the juxtamembrane parts of cytokine receptors 
(Murakami et al., 1991). 
Other signal transduction pathways are also initiated at 
the activated cytokine receptor complexes; these path- 
ways are dependent on more C-terminal regions in the 
receptors. For instance, members of the Src family of ki- 
nases bind to the C-terminal tail of the IL-2 13 receptor 
(Hatakeyama et al., 1991) and to gp130 (Ernst et al., 1994). 
Moreover, whereas JAK kinases bind to the juxtamem- 
brane part of the common 13 subunit of IL-3, IL-5, and GM- 
CSF, deletion of the C-terminus abrogates Shc phosphory- 
lation, Ras activation, and induction of c-fos and c-jun 
(Sato et al., 1993). Likewise, a region C-terminal of the 
JAK kinase-binding site of the G-CSF receptor mediates 
induction of granulocyte-specific genes (Fukunaga et al., 
1993). 
The fact that certain receptor subunits/signal transduc- 
ers are shared by several cytokines, as well as the fact 
that different receptors may bind and activate the same 
JAK kinases and possibly also share other signal transduc- 
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tion molecules, provides an explanation for the functional 
redundancy and pleiotropy of different cytokines. Con- 
versely, the presence of unique epitopes in receptors or 
receptor combinations may allow the transduction of spe- 
cific signals that mediate unique properties o~' the different 
cytokines. 
Sharing of Signal Transduction Pathways between 
Tyrosine Kinase Receptors and 
Cytokine Receptors 
There is no sharp division in the modes of signaling be- 
tween tyrosine kinase receptors and cytokine receptors. 
EGF and PDGF, acting via tyrosine kinase receptors, in- 
duce the phosphorylation of STATI~, perhaps directly or 
via activation of JAK kinases (Fu and Zhang, 1993; Ruff- 
Jamison et al., 1993; Sadowski et al., 1993; Silvennoinen 
et al., 1993). Moreover, after activation of cytokine recep- 
tors, JAK kinases or possibly other kinases phosphorylate 
the cytokine receptors themselves. This gives SH2 do- 
main-containing signal transduction molecules the possi- 
bility to interact with the cytokine receptors and initiate 
pathways initially identified for tyrosine kinase receptors, 
e.g., leading to activation of Ras and PI3-kinase (Boulton 
et al., 1994; Mui and Miyajima, 1994). 
Antigen Receptors 
The T cell receptor is composed of transmembrane pro- 
teins with very short cytoplasmic sequences, which are 
associated with a large number of invariant subunits also 
lacking intrinsic enzymatic activities, but capable of inter- 
acting with cytoplasmic tyrosine kinases (Figure 1) (for 
reviews see Cambier and Jensen, 1994; Weiss and Litt- 
man, 1994). The invariant subu nits (1,, ~, ~, C,, and 11 chains) 
contain one to three copies of a conserved 26 amino acid 
motif of pairs of tyrosine and leucine residues (Reth, 1989), 
called the antigen recognition activation motif (ARAM; also 
called tyrosine-based activation motif, or antigen receptor 
homology 1). Tyrosine kinases of the Src family bind to 
the T cell receptor even in the resting state. In conjunction 
with receptor activation, the tyrosine residues in the ARAMs 
are phosphorylated, presumably by Src family kinases (in 
T cells primarily Lck). This gives another tyrosine kinase, 
ZAP-70, which has two SH2 domains, the opportunity to 
bind to the phosphorylated sites, after which it becomes 
activated by phosphorylation on tyrosine residues, most 
likely also by Src family tyrosine kinases (Iwashima et al., 
1994; Letourneu rand Klausner, 1992). The precise mech- 
anism that triggers antigen receptor activation and phos- 
phorylation of the ARAM sequences is not known, al- 
though a possible scenario is that antigen binding causes 
receptor aggregation that makes possible interactions and 
cross-phosphorylation of tyrosine kinases in the Src fam- 
ily. Consistent with this possibility are the observations 
that chimeric molecules consisting of cytoplasmic parts 
of ARAM-containing T cell receptor subunits and extracel- 
lular domains of other molecules mediate activation of T 
cells after cross-linking (Letourneur and Klausner, 1992; 
Irving and Weiss, 1991; Romeo and Seed, 1991). 
The B cell receptor and Fc receptors also occur in 
complexes containing signal transducing molecules with 
ARAMs, suggesting similar mechanisms of signal trans- 
duction (Clark et al., 1994; Law et al., 1993; Ravetch, 
1994). Interestingly, a sequential activation of Src family 
members and ZAP-70/Syk family members may also be 
involved in cytokine signaling. The G-CSF receptor has 
been shown to be associated with Lyn, a member of the 
Src family; after stimulation, an ARAM-like motif in the 
C-terminus of the G-CSF receptor is phosphorylated, 
which binds Syk leading to its activation (Corey et al., 
1994). 
TNF Receptor Family 
An interesting variation on the "activation by oligomeriza- 
tion" theme is provided by members of the TNF receptor 
family, which are involved in regulation of cytotoxicity, 
apoptosis, and proliferation (for reviews see Bazan, 1993; 
Smith et al., 1994). TNF occurs as two forms, TNFa and 
TNF~, which both binds to two different receptors, TNF 
receptor 1 and 2 (p55 and p75, respectively). The TNFs 
are nondisulfide-bonded trimers, and elucidation of the 
X-ray structure of TNFI~ and TNF receptor 1 (Banner et al., 
1993) revealed that ligand binding induces trimerization of 
the receptor. Each TNF subunit makes contact with two 
adjacent receptor molecules, thus stabilizing the receptor 
trimer. It is likely that the activating event is receptor aggre- 
gation, but it is not clear whether there is a need for recep- 
tor trimerization, or whether receptor dimerization would 
be sufficient for activation. In support of the possibility that 
trimerization of TNF receptor 1 is, in fact, necessary for 
signal transduction, monoclonal antibodies against this 
receptor, which are expected to dimerize the receptor, 
do not lead to activation, whereas activation occurs after 
cross-linking of the monoclonals with a second antibody, 
or after stimulation by two monoclonals directed against 
different epitopes (Engelmann et al., 1990). 
A novel family of molecules that associate with the cyto- 
plasmic part of TNF receptor 2 and that may serve as 
signal transducers was recently identified (Rothe et al., 
1994); TNF receptor associated factors, TRAF1 and 
TRAF2, contain a novel region of homology and form 
homo- or heterodimers. This finding represents an im- 
portant step in the understanding of signaling from the 
TNF receptor 2, but the mode of activation of TRAFs, their 
downstream effectors, and whether related molecules are 
involved in signaling from other members in the TNF re- 
ceptor family remain to be elucidated. 
Protein-Serine/Threonine Kinase Receptors 
Transforming growth factor 15 (TGF15) is a prototype for a 
large family of structurally related factors that regulate cell 
growth and differentiation, including in addition to TGF~s, 
e.g., activins and inhibins, bone morphogenic proteins, 
and M(Jllerian inhibition substance. As far as has been 
characterized, these molecules exert their cellular effects 
by binding to heteromeric omplexes of serine/threonine 
kinase receptors (reviewed by Massague et al., 1994; Mi- 
yazono et al., 1994). 
Both type I and type II receptors have rather small cyste- 
ine-rich extracellular domains; the type I receptors, which 
are more similar to each other than to the type II receptors, 
all have a characteristic region rich in glycine and serine 
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Figure 4. Signaling via TGF~ Receptors 
Schematic illustration of the mechanism of signaling via TGFI5 recep- 
tors as suggested by Wrana et al. (1994). TGFI~ binds first to type II 
receptors that have a constitutively active serine/threonine kinase. The 
type I receptor is then incorporated in the complex and activated by 
phoaphorylation i  the GS box. Serine/threonine kinase domains are 
stippled, and GS boxes are open. 
residues (GS domain) in their cytoplasmic juxtamembrane 
domains. Both receptors are needed for signaling (Wrana 
et al., 1992), and the cytoplasmic parts of the receptors 
are not interchangeable (Okadome et al., 1994). Ligand 
binding induces a hetero-oligomeric complex of type I and 
type II receptors, most likely a heterotetramer containing 
two receptors of each type (Yamashita et al., 1994). Stud- 
ies on TGFI3-induced phosphorylation of the receptor mol- 
ecules have led to an interesting model for activation of 
the receptors (Wrana et al., 1994; Figure 4). The type I! 
receptor, which occurs in a dimer also in the absence of 
ligand (Henis et al., 1994; Chen and Derynck, 1994) and 
has a constitutively active kinase, first binds TGFI~. This 
complex then recruits the type I receptor, which can not 
bind ligand in the absence of type II receptor, resulting in 
the phosphorylation of the type I receptor on serine resi- 
dues in the GS domain. The phosphorylation presumably 
activates the type I receptor kinase that now can act on 
downstream components in the signal transduction path- 
way. Other members in the TGFI~ family also form hetero- 
meric complexes containing different members of the type 
I and type II receptor subfamilies. Thus, sequential phos- 
phorylation between the type II and type I receptors may be 
a general mechanism of receptor activation of members of 
the serine/threonine kinase receptor family. 
Is Dimerization Sufficient for Activation? 
There are several examples in which activation of recep- 
tors occurs after dimerization or oligomerization induced 
by means other than ligand binding. Many tyrosine kinase 
receptors, for instance, are activated after binding of anti- 
bodies, whereas Fab fragments generally are inactive. In- 
sertion of an extra cysteine residue in the extracellular 
juxtamembrane region of the EGF receptor led to the for- 
mation of a constitutively active dimeric receptor (Sorokin 
et al., 1994). Moreover, mutated forms of many of the tyro- 
sine kinase receptors have been identified as transforming 
oncogenes. In some cases, the activating mechanism is 
a gene rearrangement hat leads to the production of a 
fusion protein between a novel protein and the kinase do- 
main of the receptor. The fusion partners are often do- 
mains of proteins that undergo oligomerization in their nor- 
mal context. Examples include tropomyosin, which has 
been found fused to Trk (Martin-Zanca et al., 1986), the 
regulatory subunit of the cyclic AMP-dependent protein 
kinase, which has been found fused to Ret (Takahashi et 
al., 1985), and sequences from Tpr, containing a leucine 
zipper, which has been found fused to Met (Park et al., 
1986; Rodrigues and Park, 1994) as well as to Trk (Greco 
et al., 1992). Another mechanism is exemplified by the Neu 
(ErbB2) oncogene product, which obtained transforming 
activity by a single amino acid exchange in the transmem- 
brane region that promotes receptor aggregation (Weiner 
et al., 1989). In these cases, artificially induced receptor 
dimerization leads to activation of the kinase domains and 
autophosphorylation i a ligand-independent manner. 
Also cytokine receptors can acquire transforming prop- 
erties after mutation. A constitutively active EPO receptor 
mutant was found to have an arginine residue replaced 
with a cysteine residue in a region corresponding to the 
receptor dimer interface of the related GH receptor; this 
resulted in the formation of a disulfide bond that stabilized 
the receptor dimer in a ligand-independent manner (Wa- 
towich et al., 1992). This finding further supports the con- 
cept that dimerization is sufficient for activation of many 
receptor types. 
Antagonists 
There are many examples of tyrosine kinase receptors and 
cytokine receptors that after mutations in their cytoplasmic 
domains act in a dominant negative manner, i.e., when 
expressed in cells with the corresponding wild-type recep- 
tor, they attenuate the signals induced by ligands. The 
mechanism for the dominant negative effect is that the 
wild-type receptors after ligand binding are locked up in 
sterile heteromeric omplexes with the mutated receptors. 
These findings provide support for the notion that dimer- 
ization of wild-type receptors is necessary for activation 
of many receptor types; however, alternative modes for 
activation have not been excluded. Another way in which 
the oligomerization process can be antagonized is through 
mutated versions of certain ligands. For example, muta- 
tion of one of the two receptor-binding sites in GH yielded 
a G H protein with antagonistic properties (Fuh et al., 1992). 
Moreover, mutation of a glutamic acid residue in GM-CSF 
(Glu-21) that is important for the interaction with the com- 
mon 13 subunit (Hercus et al., 1994), mutation of Tyr-124 
in IL-4, which is important for interaction with the common 
~, subunit (Kruse et al., 1992), or mutation of Tyr-31 and 
Gly-35 in IL-6, which are important for interaction with the 
gp 130 signal transducer (Savi no et al., 1994), yielded mol- 
ecules with antagonistic effects in their respective systems. 
It is possible that inhibition of receptor oligomerization is 
a generally applicable method to antagonize growth factor 
and cytokine action. Antagonistic ligands and antibodies 
may have particular clinical utility in conditions of overacti= 
vity of growth factors and cytokines, since they can act 
specifically. 
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Conclusions 
It is now well established that several receptor types are 
activated through ligand-induced receptor dimerization or 
oligomerization. Dimerization combines accuracy with 
flexibility; there is specificity in binding of the ligand to the 
receptors and flexibility in the assembly of different homo- 
or heterodimeric receptor subunits depending on which 
receptors and signal transducers are expressed by a par- 
ticular cell. There are also examples of receptors that do 
not dimerize after ligand binding, e.g., the serpentine re- 
ceptor family, which transverses the cell membrane seven 
times and couples to G proteins, and ion channel recep- 
tors. However, for receptor molecules that are anchored 
in the membrane with a single transmembrane domain, 
dimerization or oligomerization may be a general mecha- 
nism for receptor activation. 
A" general feature of receptors generating growth stimu- 
latory signals seems to be activation of tyrosine kinases 
in the receptor complex. Although the exact mechanisms 
for activation of the kinases remain to be elucidated, inter- 
actions and cross-phosphorylations between identical or 
related kinases induced by receptor dimerization are com- 
mon. The resulting phosphorylations of tyrosine residues 
on receptor and signal transducing components trigger 
interactions with SH2-containing molecules (see Cohen 
et al., 1995). Growth inhibitory signals from the activated 
TGFI~ receptor complex involve phosphorylation on ser- 
ine/threonine residues in yet unknown substrates. Thus, 
much of intracellular signaling is regulated by phosphory- 
lation events. To understand the regulation of signal trans- 
duction, it will therefore be important to characterize not 
only the kinases involved, but also the phosphatases that 
counteract the effects of kinases (see Hunter, 1995 [this 
issue of Cell]). 
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